Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12657923,peak plasma concentrations,"The peak plasma concentrations were 2290 microg/L and 2900 microg/L, respectively.",Toxicokinetics of nortriptyline and amitriptyline: two case reports. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657923/),[μg] / [l],2290,154,DB00540,Nortriptyline
,12657923,peak plasma concentrations,"The peak plasma concentrations were 2290 microg/L and 2900 microg/L, respectively.",Toxicokinetics of nortriptyline and amitriptyline: two case reports. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657923/),[μg] / [l],2900,155,DB00540,Nortriptyline
,3680602,half-life,"The mean half-life in the 5- to 12-year-olds was 20.8 +/- 7.2 (range, 11.2 to 42.5) hours and in the 13- to 16-year-olds was 31.1 +/- 19.8 (range, 14.2 to 89.4) hours.",Child and adolescent nortriptyline single dose pharmacokinetic parameters: final report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680602/),h,20.8,2754,DB00540,Nortriptyline
,3680602,half-life,"The mean half-life in the 5- to 12-year-olds was 20.8 +/- 7.2 (range, 11.2 to 42.5) hours and in the 13- to 16-year-olds was 31.1 +/- 19.8 (range, 14.2 to 89.4) hours.",Child and adolescent nortriptyline single dose pharmacokinetic parameters: final report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680602/),h,31.1,2755,DB00540,Nortriptyline
less,1815435,clearance,Two slow metabolizers were identified (clearance less than 0.10 L/kg/h).,Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815435/),[l] / [h·kg],0.10,8081,DB00540,Nortriptyline
,1494978,F,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.044,8161,DB00540,Nortriptyline
,1494978,MD,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.044,8162,DB00540,Nortriptyline
,1494978,MD,"The estimated F value, a fraction of dose reached at systemic circulation, and the MD value, a fraction metabolized to NRT, were 0.044 and 0.020, respectively, after acute administration, indicating first-pass metabolism of AMT.",Pharmacokinetic analysis of amitriptyline and its demethylated metabolite in serum and brain of rats after acute and chronic oral administration of amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1494978/),,0.020,8163,DB00540,Nortriptyline
,852498,relative bioavailability,"As determined from the ratio between corresponding areas, the relative bioavailability of the oral dose was 66 +-21 S.D. per cent.",First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/852498/),%,66,17095,DB00540,Nortriptyline
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],510,21188,DB00540,Nortriptyline
,1771652,Plasma concentrations,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),[ng] / [ml],320,21189,DB00540,Nortriptyline
,1771652,half-life,Plasma concentrations of AMI (510 ng/ml) and nortriptyline (NOR; 320 ng/ml) were very high and the half-life of AMI was about 120 h.,Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),h,120,21190,DB00540,Nortriptyline
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.55,21191,DB00540,Nortriptyline
,1771652,metabolic ratio,"The debrisoquine metabolic ratio was 0.55 and 0.79 on two occasions, which shows that she had no deficiency of cytochrome P450IID6.",Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele--a slowly reversible interaction with fluoxetine. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1771652/),,0.79,21192,DB00540,Nortriptyline
,9597561,area under the concentration--time curve (AUC0-24),"Mean values for area under the concentration--time curve (AUC0-24) for the OROS and IR formulations were 1,265 and 1,393 ng.",Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597561/),ng,"1,265",29397,DB00540,Nortriptyline
,9597561,area under the concentration--time curve (AUC0-24),"Mean values for area under the concentration--time curve (AUC0-24) for the OROS and IR formulations were 1,265 and 1,393 ng.",Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrochloride formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9597561/),ng,"1,393",29398,DB00540,Nortriptyline
,1133723,bioavailability,"The predicted values of bioavailability ranged from 45 to 85%, consistent with experimentally derived estimates of nortriptyline availability.",Comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1133723/),%,45 to 85,29849,DB00540,Nortriptyline
,2731406,plasma half-lives,The plasma half-lives of both enantiomers were 8 to 9 hours.,Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),h,8 to 9,30057,DB00540,Nortriptyline
,2731406,renal clearance,"The renal clearance of unbound (-)E-10-OH-NT (0.57 +/- 0.16 L.kg-1.hr-1), on the other hand, exceeded that of (+)E-10-OH-NT (0.44 +/- 0.14 L.kg-1.hr-1) (p less than 0.005), which suggests enantioselective tubular secretion.",Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),[l] / [h·kg],0.57,30058,DB00540,Nortriptyline
,2731406,renal clearance,"The renal clearance of unbound (-)E-10-OH-NT (0.57 +/- 0.16 L.kg-1.hr-1), on the other hand, exceeded that of (+)E-10-OH-NT (0.44 +/- 0.14 L.kg-1.hr-1) (p less than 0.005), which suggests enantioselective tubular secretion.",Stereoselective disposition of racemic E-10-hydroxynortriptyline in human beings. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2731406/),[l] / [h·kg],0.44,30059,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB00540,Nortriptyline
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB00540,Nortriptyline
,7721229,elimination half-life time (t1/2,"Kinetics of amitriptyline (AMI), its demethylated metabolites nortriptyline (NOR) and demethylnortriptyline (DM-NOR), and its hydroxylated metabolites, the E and Z isomers or 10-hydroxy-amitriptyline (E- and Z-10-OH-AMI) and of 10-hydroxynortriptyline (E- and Z-10-OH-NOR) were studied in plasma and brain from Swiss CD1 mice after six successive intraperitoneal injections of amitriptyline (10 mg/kg) administered every elimination half-life time (t1/2 = 3.1 h) to obtain the steady state.",Mice plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after half-life repeated administration. Comparison with acute administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7721229/),h,3.1,50913,DB00540,Nortriptyline
,34093211,IC50,Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 µM.,"Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34093211/),μM,28.6,51397,DB00540,Nortriptyline
,34093211,IC50,Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC50 values of 28.6 and 40.4 µM.,"Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34093211/),μM,40.4,51398,DB00540,Nortriptyline
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00540,Nortriptyline
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00540,Nortriptyline
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00540,Nortriptyline
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00540,Nortriptyline
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00540,Nortriptyline
,7389249,unbound fraction,"The mean unbound fraction of AT and NT in plasma was 5.4% and 8.3%, respectively.",Interindividual differences in amitriptyline demethylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,5.4,56807,DB00540,Nortriptyline
,7389249,unbound fraction,"The mean unbound fraction of AT and NT in plasma was 5.4% and 8.3%, respectively.",Interindividual differences in amitriptyline demethylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,8.3,56808,DB00540,Nortriptyline
,7389249,systemic availability,The mean systemic availability of oral relative to intramuscular AT and NT was 43% and 61%.,Interindividual differences in amitriptyline demethylation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,43,56809,DB00540,Nortriptyline
,7389249,systemic availability,The mean systemic availability of oral relative to intramuscular AT and NT was 43% and 61%.,Interindividual differences in amitriptyline demethylation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),%,61,56810,DB00540,Nortriptyline
,7389249,oral blood clearance,The calculated mean oral blood clearance of AT as measured by dose (oral)/AUC was 1.6 1/min.,Interindividual differences in amitriptyline demethylation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),[1] / [min],1.6,56811,DB00540,Nortriptyline
,7389249,oral clearance,The estimated oral clearance of AT from demethylation ranged from 0.21 to 1.80 1/min.,Interindividual differences in amitriptyline demethylation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389249/),[1] / [min],0.21 to 1.80,56812,DB00540,Nortriptyline
,25989225,CMAX,The range of amitriptyline CMAX for the remaining fasted dogs (n = 3) was 22.8-64.5 ng/mL compared to 30.6-127 ng/mL for the fed dogs (n = 5).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[ng] / [ml],22.8-64.5,58327,DB00540,Nortriptyline
,25989225,CMAX,The range of amitriptyline CMAX for the remaining fasted dogs (n = 3) was 22.8-64.5 ng/mL compared to 30.6-127 ng/mL for the fed dogs (n = 5).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[ng] / [ml],30.6-127,58328,DB00540,Nortriptyline
,25989225,AUCINF,The range of the amitriptyline AUCINF for the three fasted dogs was 167-720 h·ng/mL compared to 287-1146 h·ng/mL for fed dogs.,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[h·ng] / [ml],167-720,58329,DB00540,Nortriptyline
,25989225,AUCINF,The range of the amitriptyline AUCINF for the three fasted dogs was 167-720 h·ng/mL compared to 287-1146 h·ng/mL for fed dogs.,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),[h·ng] / [ml],287-1146,58330,DB00540,Nortriptyline
,25989225,relative bioavailability,The relative bioavailability of amitriptyline in fasted dogs compared to fed dogs was 69-91% (n = 3).,Evaluation of the pharmacokinetics of oral amitriptyline and its active metabolite nortriptyline in fed and fasted Greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989225/),%,69-91,58331,DB00540,Nortriptyline
,1537779,plasma level,The mean plasma level was 89.9 ng/ml.,Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1537779/),[ng] / [ml],89.9,68477,DB00540,Nortriptyline
,4023050,half-life,The results indicate that amitriptylinoxide is more rapidly absorbed than amitriptyline and eliminated with a mean half-life of 1.5 hours.,Single oral dose pharmacokinetics of amitriptylinoxide and amitriptyline in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4023050/),h,1.5,77762,DB00540,Nortriptyline
,7366812,minimum levels,"The fluctuation between maximal and minimal drug levels within the dosage interval was found to be more pronounced than with a t.i.d. dosage regimen, but still limited (mean ratio = 1.54; range = 1.0--2.16), and the minimum levels (mean = 102 ng/ml; range 46--250 ng/ml) were well compatible with published t.i.d. data.",Pharmacokinetic aspects on once-daily nortriptyline administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7366812/),[ng] / [ml],102,84824,DB00540,Nortriptyline
,7366812,biological half-life,The biological half-life (mean = 39 h; range 24--86 h) agreed well with previously published data for volunteers.,Pharmacokinetic aspects on once-daily nortriptyline administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7366812/),h,39,84825,DB00540,Nortriptyline
,7957453,tmax,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,0.37,85886,DB00540,Nortriptyline
,7957453,tmax,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,0.42,85887,DB00540,Nortriptyline
,7957453,t1/2,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,3.2,85888,DB00540,Nortriptyline
,7957453,t1/2,"Absorption and elimination of AMI were rapid (tmax = 0.37 h and 0.42 h, and t1/2 = 3.2 h and 3.6 h in plasma and brain, respectively).",Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957453/),h,3.6,85889,DB00540,Nortriptyline
,4049459,t 1/2,"However, the variation in t 1/2 was extremely large in both the CAPD and normal renal function groups (range 15-34 h and 24-70 h, respectively).",Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049459/),h,15-34,87717,DB00540,Nortriptyline
,4049459,t 1/2,"However, the variation in t 1/2 was extremely large in both the CAPD and normal renal function groups (range 15-34 h and 24-70 h, respectively).",Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049459/),h,24-70,87718,DB00540,Nortriptyline
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB00540,Nortriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB00540,Nortriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB00540,Nortriptyline
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB00540,Nortriptyline
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB00540,Nortriptyline
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB00540,Nortriptyline
,12012142,area under the plasma concentration-time curve (AUC(AT)),"The mean area under the plasma concentration-time curve (AUC(AT)) of CYP2C19 poor metabolizers (PMs, n=6) was significantly higher than that of CYP2C19 extensive metabolizers (EMs, n=6) (2207+/-501 ng/ml x h(-1) vs 1596+/-406 ng/ml x h(-1), P<0.05).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],2207,96953,DB00540,Nortriptyline
,12012142,area under the plasma concentration-time curve (AUC(AT)),"The mean area under the plasma concentration-time curve (AUC(AT)) of CYP2C19 poor metabolizers (PMs, n=6) was significantly higher than that of CYP2C19 extensive metabolizers (EMs, n=6) (2207+/-501 ng/ml x h(-1) vs 1596+/-406 ng/ml x h(-1), P<0.05).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],1596,96954,DB00540,Nortriptyline
,12012142,AUC(NT(0-)(infinity)()),"In contrast, the mean AUC(NT(0-)(infinity)()) of PMs was significantly lower than that of EMs (294+/-70 ng/ml x h(-1) vs 684+/-130 ng/ml x h(-1), P<0.0001).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],294,96955,DB00540,Nortriptyline
,12012142,AUC(NT(0-)(infinity)()),"In contrast, the mean AUC(NT(0-)(infinity)()) of PMs was significantly lower than that of EMs (294+/-70 ng/ml x h(-1) vs 684+/-130 ng/ml x h(-1), P<0.0001).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[ml·ng] / [h],684,96956,DB00540,Nortriptyline
,12012142,clearance,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),[h·l] / [kg],0.41,96957,DB00540,Nortriptyline
,12012142,time to peak plasma concentration,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),h,4.0,96958,DB00540,Nortriptyline
,12012142,time to peak plasma concentration,"Other pharmacokinetic parameters such as clearance, half-life, maximum plasma concentration, and time to peak plasma concentration showed no significant difference between PMs and EMs (0.41+/-0.12 l /h x kg(-1) vs 0.50+/-0.15 l /h x kg(-1), 25.0+/-6.2 h vs 24.1+/-4.4 h, 96+/-25 ng/ml vs 75+/-27 ng/ml, 4.0+/-1.4 h vs 3.7+/-1.5 h, respectively).",The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012142/),h,3.7,96959,DB00540,Nortriptyline
,17944232,AUC(0-infinity),The mean AUC(0-infinity) of free nortritpyline in ORM1 * F/ * F1 subjects was significantly higher than that in ORM1 * F1/ * S and ORM1 * S/ * S subjects [(119.1 +/- 74.4) ng x mL(-1) x h vs (51.4 +/- 23.2) ng x mL(-1) x h and (42.4 +/- 11.6) ng x mL(-1) x h].,[Influence of ORM1 polymorphism on serum concentration of free nortriptyline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944232/),[h·ng] / [ml],119.1,104670,DB00540,Nortriptyline
,17944232,AUC(0-infinity),The mean AUC(0-infinity) of free nortritpyline in ORM1 * F/ * F1 subjects was significantly higher than that in ORM1 * F1/ * S and ORM1 * S/ * S subjects [(119.1 +/- 74.4) ng x mL(-1) x h vs (51.4 +/- 23.2) ng x mL(-1) x h and (42.4 +/- 11.6) ng x mL(-1) x h].,[Influence of ORM1 polymorphism on serum concentration of free nortriptyline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944232/),[h·ng] / [ml],51.4,104671,DB00540,Nortriptyline
,17944232,AUC(0-infinity),The mean AUC(0-infinity) of free nortritpyline in ORM1 * F/ * F1 subjects was significantly higher than that in ORM1 * F1/ * S and ORM1 * S/ * S subjects [(119.1 +/- 74.4) ng x mL(-1) x h vs (51.4 +/- 23.2) ng x mL(-1) x h and (42.4 +/- 11.6) ng x mL(-1) x h].,[Influence of ORM1 polymorphism on serum concentration of free nortriptyline]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944232/),[h·ng] / [ml],42.4,104672,DB00540,Nortriptyline
,7428796,Pd1/2,It was possible to detect DTS for 228-300 h after the last oral dose and the mean Pd1/2 of this decline of pharmacodynamic effect was observed to be 135 h.,Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,135,106227,DB00540,Nortriptyline
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,37.7,106228,DB00540,Nortriptyline
,7428796,elimination plasma half-life (t1/2),"However, no measurable amount of AT or NT was present after 84 h and the mean elimination plasma half-life (t1/2) of AT and NT were 37.7 and 38.9 h, respectively.",Decreased tyramine sensitivity after discontinuation of amitriptyline therapy. An index of pharmacodynamic half-life. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7428796/),h,38.9,106229,DB00540,Nortriptyline
,29333862,LOD,"The LOD for the drug was obtained to be 0.007, 0.009 and 0.021 μg ml-1 in deionized water, urine and blood samples of human subjects, respectively.",Pharmacokinetic determination and analysis of nortriptyline based on GC-MS coupled with hollow-fiber drop-to-drop solvent microextraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333862/),[μg] / [ml],0.007,106340,DB00540,Nortriptyline
,29333862,LOD,"The LOD for the drug was obtained to be 0.007, 0.009 and 0.021 μg ml-1 in deionized water, urine and blood samples of human subjects, respectively.",Pharmacokinetic determination and analysis of nortriptyline based on GC-MS coupled with hollow-fiber drop-to-drop solvent microextraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333862/),[μg] / [ml],0.009,106341,DB00540,Nortriptyline
,29333862,LOD,"The LOD for the drug was obtained to be 0.007, 0.009 and 0.021 μg ml-1 in deionized water, urine and blood samples of human subjects, respectively.",Pharmacokinetic determination and analysis of nortriptyline based on GC-MS coupled with hollow-fiber drop-to-drop solvent microextraction technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29333862/),[μg] / [ml],0.021,106342,DB00540,Nortriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,70,113444,DB00540,Nortriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,105,113445,DB00540,Nortriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,61.0,113446,DB00540,Nortriptyline
,2109680,plasma,"In the second group, addition of valpromide resulted in a significant increase of antidepressant plasma levels: from 70.5 +/- 35 to 105.5 +/- 49 ng/ml (p less than 0.0003) for amitriptyline, and from 61.0 +/- 34 to 100.5 +/- 65 ng/ml (p less than 0.01) for nortriptyline.",[Valpromide-amitriptyline interaction. Increase in the bioavailability of amitriptyline and nortriptyline caused by valpromide]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2109680/),ng,100.5,113447,DB00540,Nortriptyline
,1570375,renal plasma clearance,The renal plasma clearance of AT-NO varied between 75 and 265 ml/min in the six volunteers.,Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1570375/),[ml] / [min],75 and 265,116255,DB00540,Nortriptyline
,2255664,Run time,Run time was approximately 14 min.,An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),min,14,117067,DB00540,Nortriptyline
,2255664,flow,"5 mu 250 x 4.6 mm column, a mobile phase consisting of aqueous ammonium: methanol: acetonitrile (0.8:6.2:93, v/v), and flow of 1.3 ml/min.",An automated method for the determination of nortriptyline and its isomeric 10-hydroxylated metabolites in plasma by high pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2255664/),[ml] / [min],1.3,117068,DB00540,Nortriptyline
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.68,125236,DB00540,Nortriptyline
,8436164,plasma ratio,"There was only a minor pharmacokinetic interaction between amitriptyline (AMT) and toloxatone, with a small increase in the AMT/NT (nortriptyline) plasma ratio: 0.68 before and 0.78 after toloxatone.",Minor and clinically non-significant interaction between toloxatone and amitriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8436164/),,0.78,125237,DB00540,Nortriptyline
,6808544,free fraction,The free fraction of OHNT in plasma of healthy subjects was about 35%.,Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6808544/),%,35,126579,DB00540,Nortriptyline
,21999196,Δ heart rate,"At t(max) at 8 h post dose, nortriptyline increased the heart rate response to posture change in all subjects with mean (95% CI) Δ heart rate values of 7.4 (3.6, 11.3) beats min(-1) on active standing (P = 0.0009) and 4.8 (2.0, 7.6) beats min(-1) on head-up tilt (P = 0.002), but no difference was observed between haplotype groups.",Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999196/),[beats] / [min],7.4,132670,DB00540,Nortriptyline
,21999196,Δ heart rate,"At t(max) at 8 h post dose, nortriptyline increased the heart rate response to posture change in all subjects with mean (95% CI) Δ heart rate values of 7.4 (3.6, 11.3) beats min(-1) on active standing (P = 0.0009) and 4.8 (2.0, 7.6) beats min(-1) on head-up tilt (P = 0.002), but no difference was observed between haplotype groups.",Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21999196/),[beats] / [min],4.8,132671,DB00540,Nortriptyline
,711927,Peak amitriptyline plasma concentrations,Peak amitriptyline plasma concentrations ranged from 10.8 to 43.7 ng/ml.,Contribution to the pharmacokinetics of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),[ng] / [ml],10.8 to 43.7,143143,DB00540,Nortriptyline
,711927,elimination half-life,The mean elimination half-life was 36.1 hours.,Contribution to the pharmacokinetics of amitriptyline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),h,36.1,143144,DB00540,Nortriptyline
,711927,first-pass metabolism,The mean estimated first-pass metabolism of amitriptyline was 60 per cent.,Contribution to the pharmacokinetics of amitriptyline. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),%,60,143145,DB00540,Nortriptyline
,711927,peak concentrations,"Significant quantities of the metabolite, nortriptyline, were produced although peak concentrations ranged from only 5.9 to 12.3 ng/ml.",Contribution to the pharmacokinetics of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/711927/),[ng] / [ml],5.9 to 12.3,143146,DB00540,Nortriptyline
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],135--185,147714,DB00540,Nortriptyline
,7424564,Clearance,"Clearance values of 135--185 and 190--200 ml/min were obtained for amitriptyline and nortriptyline, respectively.",Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],190,147715,DB00540,Nortriptyline
,7424564,clearance,A clearance of 140 ml/min was obtained in a uremic patient with AV block II due to digitoxin intoxication.,Hemoperfusion with Amberlite resin in the treatment of self-poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7424564/),[ml] / [min],140,147716,DB00540,Nortriptyline
,3750370,normalized total nortriptyline concentration,The mean normalized total nortriptyline concentration for the smokers of 118 +/- 33 ng/ml was significantly lower than the nonsmokers' mean value of 158 +/- 35 ng/ml.,Effects of smoking on nortriptyline plasma concentrations in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750370/),[ng] / [ml],118,150771,DB00540,Nortriptyline
,3750370,normalized total nortriptyline concentration,The mean normalized total nortriptyline concentration for the smokers of 118 +/- 33 ng/ml was significantly lower than the nonsmokers' mean value of 158 +/- 35 ng/ml.,Effects of smoking on nortriptyline plasma concentrations in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750370/),[ng] / [ml],158,150772,DB00540,Nortriptyline
,3750370,normalized free plasma concentrations,The mean normalized free plasma concentrations for the smokers of 11.4 +/- 3.5 ng/ml was not different from the nonsmokers' mean concentrations of 11.5 +/- 2.6 ng/ml.,Effects of smoking on nortriptyline plasma concentrations in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750370/),[ng] / [ml],11.4,150773,DB00540,Nortriptyline
,3750370,normalized free plasma concentrations,The mean normalized free plasma concentrations for the smokers of 11.4 +/- 3.5 ng/ml was not different from the nonsmokers' mean concentrations of 11.5 +/- 2.6 ng/ml.,Effects of smoking on nortriptyline plasma concentrations in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3750370/),[ng] / [ml],11.5,150774,DB00540,Nortriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,85.3,154839,DB00540,Nortriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,88.4,154840,DB00540,Nortriptyline
,20954218,recovery,"The recovery was 85.3, 88.4 and 80.7% for amitriptyline, nortriptyline and doxepin respectively.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),%,80.7,154841,DB00540,Nortriptyline
,20954218,Total run time,"Total run time was 1.2 min only for each sample, which makes it possible to analyze more than 400 samples per day.",Development and validation of amitriptyline and its metabolite in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20954218/),min,1.2,154842,DB00540,Nortriptyline
,6490962,half-life,"The prepubertals had a shorter mean half-life (17.6 +/- 3.7 hours) than some adult groups and twice a day dosage would, therefore, be more appropriate for many children.",Nortriptyline pharmacokinetic parameters in depressed children and adolescents: preliminary data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6490962/),h,17.6,158107,DB00540,Nortriptyline
,6490962,half-life,"Although the mean half-life (27.1 +/- 17.1 hours) for the adolescent group suggested that once a day dosage would be sufficient, some adolescents would need twice a day dosage for optimum plasma level control because there was a wide range (14.1 to 76.2 hours).",Nortriptyline pharmacokinetic parameters in depressed children and adolescents: preliminary data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6490962/),h,27.1,158108,DB00540,Nortriptyline
,7203728,peak time,AMI was absorbed rather slowly (mean peak time 10.4 +/- 1.6 hrs) but very efficiently (F: 0.59-0.75).,Pharmacokinetics of amitriptyline in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),h,10.4,159198,DB00540,Nortriptyline
,7203728,F,AMI was absorbed rather slowly (mean peak time 10.4 +/- 1.6 hrs) but very efficiently (F: 0.59-0.75).,Pharmacokinetics of amitriptyline in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),,0.59-0.75,159199,DB00540,Nortriptyline
,7203728,appearance clearance,The rate of formation of nortriptyline (NT) as well as the appearance clearance values (0.18-0.45 l/h/kg) of AMI were significantly lower than those previously described for younger subjects.,Pharmacokinetics of amitriptyline in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203728/),[l] / [h·kg],0.18-0.45,159200,DB00540,Nortriptyline
,976307,biological half-life,"The calculated biological half-life of amitriptyline was about 17 hours, a figure which differs considerably from previously calculated values for volunteers, but is in accordance with some newer results from patients.",Pharmacokinetics of amitriptyline infused intravenously in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/976307/),h,17,160992,DB00540,Nortriptyline
,18780336,absolute oral bioavalability (F),"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,6.30,168296,DB00540,Nortriptyline
,18780336,first-pass effects,"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,9,168297,DB00540,Nortriptyline
,18780336,first-pass effects,"After oral administration of amitriptyline, approximately 1.50% of the dose was not absorbed, the extent of absolute oral bioavalability (F) was approximately 6.30%, and the hepatic and intestinal first-pass effects of amitriptyline were approximately 9% and 87% of the oral dose, respectively.","Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,87,168298,DB00540,Nortriptyline
,18780336,F,The lower F value of amitriptyline in rats than that in humans (46 +/- 48%) was due to grater metabolism of amitriptyline in rats' liver and/or small intestine.,"Pharmacokinetics of amitriptyline and one of its metabolites, nortriptyline, in rats: little contribution of considerable hepatic first-pass effect to low bioavailability of amitriptyline due to great intestinal first-pass effect. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18780336/),%,46,168299,DB00540,Nortriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],80.6,168463,DB00540,Nortriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],52.6,168464,DB00540,Nortriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],85.3,168465,DB00540,Nortriptyline
,7751409,steady-state concentrations (Css),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[ng] / [ml],90,168466,DB00540,Nortriptyline
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],42.4,168467,DB00540,Nortriptyline
,7751409,apparent oral clearances (CLor),"The means and (SEM) of the steady-state concentrations (Css) of AMI, NTRIP, FLU, and NFLU were 80.6 (14.2), 52.6 (10.3), 85.3 (16.1), and 90 (13.6) ng/mL, respectively, and the apparent oral clearances (CLor) of AMI and FLU were 42.4 (8.6) and 14.9 (2.5) L/hr, respectively.",Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),[l] / [h],14.9,168468,DB00540,Nortriptyline
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,0.75,168469,DB00540,Nortriptyline
,7751409,steady-state concentration ratio (Css(m)/Css),The metabolite/drug steady-state concentration ratio (Css(m)/Css) for NTRIP/AMI was 0.75 (0.14) and for NFLU/FLU was 1.27 (0.17).,Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751409/),,1.27,168470,DB00540,Nortriptyline
,9230637,level/dose (L/D) ratio,"At postpartum Week 2, the women developed a mean level/dose (L/D) ratio for NTP of 1.11 (range 0.37 to 3.23), and subsequently experienced an increase in the L/D ratios which continued through Week 6.",Effects of the postpartum period on nortriptyline pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9230637/),,1.11,169093,DB00540,Nortriptyline
,20570077,flow rate,"Chromatographic separation was performed on a XB-C4 column (4.6 mm x 250 mm, 5 microm, Welch Materials) with a mobile phase consisting of 10mM ammonium acetate (0.6 per thousand formic acid)-acetonitrile (60:40, v/v) at a flow rate of 1.0 ml/min.",Validated LC-MS (ESI) assay for the simultaneous determination of amitriptyline and its metabolite nortriptyline in rat plasma: application to a pharmacokinetic comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20570077/),[ml] / [min],1.0,174468,DB00540,Nortriptyline
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2791,176461,DB00540,Nortriptyline
,11583471,apparent oral clearance,The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole.,Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583471/),[ml] / [min],2069,176462,DB00540,Nortriptyline
,6511999,concentrations,"Twelve-hour measurements of total plasma nortriptyline following steady state administration of the drug at 10 mg every other day, 10 mg daily, and 25 mg daily were 38, 86, and 647 ng/ml and while free plasma nortriptyline concentrations were 0.37, 0.9, and 6.6 ng/ml, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),[ng] / [ml],0.37,177253,DB00540,Nortriptyline
,6511999,concentrations,"Twelve-hour measurements of total plasma nortriptyline following steady state administration of the drug at 10 mg every other day, 10 mg daily, and 25 mg daily were 38, 86, and 647 ng/ml and while free plasma nortriptyline concentrations were 0.37, 0.9, and 6.6 ng/ml, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),[ng] / [ml],0.9,177254,DB00540,Nortriptyline
,6511999,concentrations,"Twelve-hour measurements of total plasma nortriptyline following steady state administration of the drug at 10 mg every other day, 10 mg daily, and 25 mg daily were 38, 86, and 647 ng/ml and while free plasma nortriptyline concentrations were 0.37, 0.9, and 6.6 ng/ml, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),[ng] / [ml],6.6,177255,DB00540,Nortriptyline
,6511999,Half-lives,"Half-lives calculated from samples collected at 12, 24, and 36 hours status after administration of steady state 10 mg every other day, 10 mg daily, and 25 mg daily maintenance doses were 30.4, 36.7, and 64 hours, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),h,30.4,177256,DB00540,Nortriptyline
,6511999,Half-lives,"Half-lives calculated from samples collected at 12, 24, and 36 hours status after administration of steady state 10 mg every other day, 10 mg daily, and 25 mg daily maintenance doses were 30.4, 36.7, and 64 hours, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),h,36.7,177257,DB00540,Nortriptyline
,6511999,Half-lives,"Half-lives calculated from samples collected at 12, 24, and 36 hours status after administration of steady state 10 mg every other day, 10 mg daily, and 25 mg daily maintenance doses were 30.4, 36.7, and 64 hours, respectively.",Nortriptyline capacity-limited metabolism: a case report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6511999/),h,64,177258,DB00540,Nortriptyline
,2789662,plasma levels,"Twenty-four-hour plasma levels (mean 8.8 ng/ml, SD 3.2) were significantly correlated with steady state levels at 25 mg/day (r = 0.71), steady state levels at 50 mg/day (r = 0.73), and each individual's average (plasma level/dose) (r = 0.57).",Steady state pharmacokinetics of nortriptyline in the frail elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2789662/),[ng] / [ml],8.8,188538,DB00540,Nortriptyline
,1859509,maximum plasma levels,"The tests for the parent substance amitriptylinoxide revealed maximum plasma levels of 721 and 686 ng/ml at 1.96 h (i.v. infusion) and 0.82 h (oral formulation), respectively.",[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[ng] / [ml],721,190956,DB00540,Nortriptyline
,1859509,maximum plasma levels,"The tests for the parent substance amitriptylinoxide revealed maximum plasma levels of 721 and 686 ng/ml at 1.96 h (i.v. infusion) and 0.82 h (oral formulation), respectively.",[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[ng] / [ml],686,190957,DB00540,Nortriptyline
,1859509,area under the curve from time 0 to infinity AUC (0-infinity),Mean values of 2331 (infusion) and 1714 h.ng/ml (oral formulation) were determined for the area under the curve from time 0 to infinity AUC (0-infinity).,[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[h·ng] / [ml],2331,190958,DB00540,Nortriptyline
,1859509,area under the curve from time 0 to infinity AUC (0-infinity),Mean values of 2331 (infusion) and 1714 h.ng/ml (oral formulation) were determined for the area under the curve from time 0 to infinity AUC (0-infinity).,[Plasma and urine kinetics of amitriptyline oxide and its metabolites. Comparison of intravenous infusion and oral administration in volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859509/),[h·ng] / [ml],1714,190959,DB00540,Nortriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.34,191279,DB00540,Nortriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.28,191280,DB00540,Nortriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.59,191281,DB00540,Nortriptyline
,10872574,peak blood concentrations,"The peak blood concentrations of AMT and NTR in Group I were 0.34 and 0.28 microg/mL, respectively, and those of AMT and NTR in Group II were 0.59 and 0.43 microg/mL, respectively, and were reached at 1 h after single oral administration.",Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10872574/),[μg] / [ml],0.43,191282,DB00540,Nortriptyline
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,81,191715,DB00540,Nortriptyline
,11243492,TPTs,The TPTs of AMI and NOR were 81% and 62% of the freely diffusable antipyrine.,Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243492/),%,62,191716,DB00540,Nortriptyline
,11735606,Bioavailability,"Bioavailability was found to vary between 0.17 and 0.71, depending on the genotype.",Quantitative pharmacogenetics of nortriptyline: a novel approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11735606/),,0.,194840,DB00540,Nortriptyline
,20853465,total run time,"The total run time was 2.5 min and the elution of NTP, OH-NTP and IS occurred at 1.44, 1.28 and 1.39 min, respectively; this was achieved with a mobile phase consisting of 20 mm ammonium acetate : acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPURITY C(18) column.",Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853465/),min,2.5,194957,DB00540,Nortriptyline
,20853465,flow rate,"The total run time was 2.5 min and the elution of NTP, OH-NTP and IS occurred at 1.44, 1.28 and 1.39 min, respectively; this was achieved with a mobile phase consisting of 20 mm ammonium acetate : acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on a HyPURITY C(18) column.",Development and validation of a highly sensitive LC-MS/MS method for simultaneous quantitation of nortriptyline and 10-hydroxynortriptyline in human plasma: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853465/),[ml] / [min],0.50,194958,DB00540,Nortriptyline
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB00540,Nortriptyline
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],-,195215,DB00540,Nortriptyline
,32879225,activation entropy (ΔS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ΔS) was -80.73 J/K·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [k·mol],80.73,195216,DB00540,Nortriptyline
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB00540,Nortriptyline
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB00540,Nortriptyline
,7157460,lower detection limit,The lower detection limit was 2-5 ng/ml for both drugs.,A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),[ng] / [ml],2-5,197403,DB00540,Nortriptyline
,7157460,recovery,"The method is specific for AT and NT, with a recovery of AT and NT of 68 and 71%, respectively.",A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),%,68,197404,DB00540,Nortriptyline
,7157460,recovery,"The method is specific for AT and NT, with a recovery of AT and NT of 68 and 71%, respectively.",A sensitive gas chromatographic assay for amitriptyline and nortriptyline in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7157460/),%,71,197405,DB00540,Nortriptyline
,2389248,affinity constant,The intensity of this phenomenon was a function of both the antibody affinity constant (10(9) M-1) and the neutralizing capacity (varying from 0.005 to 0.2 mg/kg) of the circulating antibodies in each immunized rabbit.,The effect of nortriptyline-specific active immunization on amitriptyline toxicity and disposition in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389248/),1/[M],10(9),198243,DB00540,Nortriptyline
,10383563,maximal plasma amitriptyline concentration Cmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),[ng] / [ml],15.3,199641,DB00540,Nortriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),h,25.7,199642,DB00540,Nortriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),[ng] / [ml],26.8,199643,DB00540,Nortriptyline
,10383563,tmax,"Following dosing with OROS (amitriptyline hydrochloride), the mean maximal plasma amitriptyline concentration Cmax (15.3 ng ml-1 ) was lower and the mean tmax (25.7 h) was longer than that associated with the equivalent IR dose administered at nighttime (26.8 ng ml-1 and 6.3 h, respectively).",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),h,6.3,199644,DB00540,Nortriptyline
,10383563,bioavailability,"The bioavailability of amitriptyline following OROS dosing was 95% relative to IR every 8 h dosing, and 89% relative to IR nighttime dosing.",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),%,95,199645,DB00540,Nortriptyline
,10383563,bioavailability,"The bioavailability of amitriptyline following OROS dosing was 95% relative to IR every 8 h dosing, and 89% relative to IR nighttime dosing.",Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383563/),%,89,199646,DB00540,Nortriptyline
,659530,sensitivity,"Using 1 ml of plasma, the sensitivity limit was 0.5 ng/ml for both substances.",Determination of amitriptyline and nortriptyline in human plasma by quantitative thin-layer chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/659530/),[ng] / [ml],0.5,204536,DB00540,Nortriptyline
,25683584,maximum plasma concentration (CMAX),The mean maximum plasma concentration (CMAX) of amitriptyline was 27.4 ng mL(-1) at 1 hour and its mean terminal half-life was 4.33 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),[ng] / [ml],27.4,208170,DB00540,Nortriptyline
,25683584,terminal half-life,The mean maximum plasma concentration (CMAX) of amitriptyline was 27.4 ng mL(-1) at 1 hour and its mean terminal half-life was 4.33 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),h,4.33,208171,DB00540,Nortriptyline
,25683584,Bioavailability,Bioavailability of oral amitriptyline was 6%.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),%,6,208172,DB00540,Nortriptyline
,25683584,CMAX,The mean CMAX of nortriptyline was 14.4 ng mL(-1) at 2.05 hours and its mean terminal half-life was 6.20 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),[ng] / [ml],14.4,208173,DB00540,Nortriptyline
,25683584,terminal half-life,The mean CMAX of nortriptyline was 14.4 ng mL(-1) at 2.05 hours and its mean terminal half-life was 6.20 hours following oral amitriptyline.,Pharmacokinetics of intravenous and oral amitriptyline and its active metabolite nortriptyline in Greyhound dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25683584/),h,6.20,208174,DB00540,Nortriptyline
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,13.7,209869,DB00540,Nortriptyline
,28674244,unbound Ki,"Terbinafine competitively inhibited amitriptyline or nortriptyline E-10-hydroxylation, with unbound Ki values of 13.7 and 12.4 nM, respectively.",Analysis of the Mechanism of Prolonged Persistence of Drug Interaction between Terbinafine and Amitriptyline or Nortriptyline. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28674244/),nM,12.4,209870,DB00540,Nortriptyline
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB00540,Nortriptyline
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB00540,Nortriptyline
,29674001,Ki,"The three main NVP metabolites (2-OH-NVP, 3-OH-NVP and 12-OH-NVP) where competitively inhibited with similar inhibitory constant values (Ki = 4.01, 3.97 and 4.40 μM, respectively).",In vitro assessment of competitive and time-dependent inhibition of the nevirapine metabolism by nortriptyline in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29674001/),μM,4.01,235000,DB00540,Nortriptyline
,29674001,Ki,"The three main NVP metabolites (2-OH-NVP, 3-OH-NVP and 12-OH-NVP) where competitively inhibited with similar inhibitory constant values (Ki = 4.01, 3.97 and 4.40 μM, respectively).",In vitro assessment of competitive and time-dependent inhibition of the nevirapine metabolism by nortriptyline in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29674001/),μM,3.97,235001,DB00540,Nortriptyline
,29674001,Ki,"The three main NVP metabolites (2-OH-NVP, 3-OH-NVP and 12-OH-NVP) where competitively inhibited with similar inhibitory constant values (Ki = 4.01, 3.97 and 4.40 μM, respectively).",In vitro assessment of competitive and time-dependent inhibition of the nevirapine metabolism by nortriptyline in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29674001/),μM,4.40,235002,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.53,241459,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.59,241460,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.25,241461,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"Enzyme kinetic studies revealed that NOR inhibited steroid 2 alpha-, 6 beta, 7 alpha-, and 16 alpha-hydroxylation in untreated rat liver with Km/Ki ratios of 0.53, 0.59, 0.25, and 0.29, respectively.",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.29,241462,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,8.8,241463,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,3.9,241464,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,0.62,241465,DB00540,Nortriptyline
,1435757,Km/Ki ratios,"When the drug was preincubated with microsomes and NADPH before testosterone hydroxylation was conducted, marked increases in the Km/Ki ratios were observed (to 8.8, 3.9, 0.62, and 13, respectively).",Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1435757/),,13,241466,DB00540,Nortriptyline
,6707156,lower limit of detection,The lower limit of detection was 2 ng/ml for all compounds except 5 ng/ml for 10-OH-NT.,Gas chromatographic--mass spectrometric determination of amitriptyline and its major metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707156/),[ng] / [ml],2,251030,DB00540,Nortriptyline
,6707156,lower limit of detection,The lower limit of detection was 2 ng/ml for all compounds except 5 ng/ml for 10-OH-NT.,Gas chromatographic--mass spectrometric determination of amitriptyline and its major metabolites in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6707156/),[ng] / [ml],5,251031,DB00540,Nortriptyline
,30452773,metabolic clearance,"The biotransformation of amitriptyline into nortriptyline was significantly different between subjects with the CYP2C19*2/*2, *2/*3, and *3/*3 genotypes and those with the other genotypes, with an estimated metabolic clearance of 17 and 61.5 L/h, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],17,261466,DB00540,Nortriptyline
,30452773,metabolic clearance,"The biotransformation of amitriptyline into nortriptyline was significantly different between subjects with the CYP2C19*2/*2, *2/*3, and *3/*3 genotypes and those with the other genotypes, with an estimated metabolic clearance of 17 and 61.5 L/h, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],61.5,261467,DB00540,Nortriptyline
,30452773,Clearance,"Clearance of amitriptyline through pathways other than biotransformation into nortriptyline was estimated as 18.8 and 30.6 L/h for subjects with the CYP2D6*10/*10 and *10/*5 genotypes and those with the other genotypes, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],18.8,261468,DB00540,Nortriptyline
,30452773,Clearance,"Clearance of amitriptyline through pathways other than biotransformation into nortriptyline was estimated as 18.8 and 30.6 L/h for subjects with the CYP2D6*10/*10 and *10/*5 genotypes and those with the other genotypes, respectively.","Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30452773/),[l] / [h],30.6,261469,DB00540,Nortriptyline
,7248140,half-life,2 The median nortriptyline half-life was 25.2 h (range 14.5-140.0 h) and the median nortriptyline clearance was 32.3 l/h (range 8.1-122.0 l/h).,The pharmacokinetics of nortriptyline in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248140/),h,25.2,271771,DB00540,Nortriptyline
,7248140,clearance,2 The median nortriptyline half-life was 25.2 h (range 14.5-140.0 h) and the median nortriptyline clearance was 32.3 l/h (range 8.1-122.0 l/h).,The pharmacokinetics of nortriptyline in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248140/),[l] / [h],32.3,271772,DB00540,Nortriptyline
